Clinical Trials · NCT03131687
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 318
- Start date
- May 2017
- Locations
- 49 sites, 4 countries
- Primary endpoint
- Change From Baseline to Week 26 in Hemoglobin A1c (HbA1c) Bayesian Dose Response